ClinicalTrials.gg
RecruitingNCT06906211LIFU_PainUpdated Aug 25, 2026

Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula

An interventional study of low intensity focused ultrasound (LIFU) in Chronic Back Pain and Chronic Pain (Back / Neck), sponsored by Washington D.C. Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Washington D.C. Veterans Affairs Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
506th of 1,092
66 · median 60
Started
2025
with 91 others
No phase
803 of 1,283
168 open now
Primary completion
2028-01
later than 253 of 347 live
Registered
1,142nd of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 506th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 92 that started in 2025, is one of 803 with no phase, reaches primary completion later than 253 of the 347 other live ones, and was the 1,142nd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

In this study, the research team will use low-intensity focused ultrasound (LIFU) to temporarily change brain activity in a brain region that is known to be involved in chronic pain. Through this, the research team hopes to learn about how the brain area works in response to pain. There are main questions this study aims to answer:

  • The effect of LIFU to inhibit the posterior region of the insula (PI) compared to sham stimulation in individuals with chronic back pain (CBP) and widespread pain symptoms.
  • The effect of LIFU to PI compared to sham stimulation to reduce pain intensity and magnitude of the Neurologic Pain Signature (NPS) in response to evoked thermal pain.
  • The effect of LIFU to PI compared to sham stimulation to reduce pain intensity and magnitude of Tonic Pain Signature in response to tonic pain.
Read the detailed description

Chronic pain is a major public health problem. An estimated 100 million Americans have experienced chronic pain producing significant economic and social burden. The estimated annual cost of chronic pain is as high as $635 billion. Pharmacological treatments frequently require the use of opioids resulting in a major epidemic of abuse in the United States. New, non-addicting treatments for pain are critically needed. Neuromodulation with low-intensity focused ultrasound (LIFU) could represent a non-pharmacological treatment for chronic pain. The millimeter spatial specificity of LIFU makes it a powerful alternative to both invasive neurosurgical procedures and other noninvasive brain stimulation techniques. One promising target to treat chronic pain is the insular cortex. The insula as a key brain area involved in both sensory and affective components of chronic pain, including central sensitization processes which occur with pain chronicity. The insula is inaccessible using conventional noninvasive neuromodulatory techniques like transcranial magnetic stimulation. In contrast, LIFU can be focused deeply and provides the spatial resolution to resolve individual sub-regions of the insula. This is relevant to pain as the posterior subregion of the insula (PI) receives nociceptive input from spinothalamic tracts, relays it to the anterior insula which integrates expectation, awareness, and emotion to form the overall experience of pain. Therefore, using LIFU can address a gap in knowledge regarding the causal role of insular subregions in modulating pain response and CS processes. The preliminary data indicate that LIFU to PI reduces laboratory measures of central sensitization and evoked pain in healthy controls but there was no such effect of LIFU to anterior insula. Building on these results, the overall objective of this proposal is to examine the effect of LIFU to PI on the central sensitization processes that are a key feature of chronic pain syndromes and on neural response to evoked and tonic pain/pain intensity. The investigators will employ well validated laboratory measures of central sensitization and multivariate measures of neural response to evoked (Neurologic Pain Signature, NPS) and tonic (Tonic Pain Signature) pain. The chronic pain condition that the investigators will focus on in this study will be chronic back pain (CBP) with widespread pain widespread pain as the back is the most common site of chronic pain, is significantly more likely to be severe in the veteran population, and it commonly occurs with features of central sensitization. Eligible participants will have CBP with symptoms of widespread pain.

03

Conditions studied

  • Chronic Back Pain
  • Chronic Pain (Back / Neck)

Browse trials for

Keywords

  • low intensity focused ultrasound
  • chronic back pain
  • chronic pain
  • functional magnetic resonance imaging
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans aged 21 to 75 with Chronic Back Pain (CBP).
  • CBP duration daily for last 3 months or half of days for last 6 months
  • Endorse pain rating of 4/10 BPI-SF
  • Evidence of widespread pain symptoms as determined by report of CBP and pain in a contralateral limb (pain in the upper, lower, left or right side of the body) in fewer than 11 sites. Upper body sites include hand, wrist, elbow or shoulder. Lower sites include hip, knee, ankle or foot.

Exclusion criteria

Exclusion Criteria:

  • Surgery recommended as primary treatment intervention for CBP
  • Current diagnosis of fibromyalgia
  • Current substance use disorder other than nicotine.
  • Psychiatric disorder and not on a stable pharmacologic regimen for ≥ 4 weeks prior to screening
  • Opiate use daily
  • Currently pregnant or breast feeding.
  • Unable to understand the consent form.
  • History of head injury with loss of consciousness for more than 5 minutes, seizures, history of stroke, brain surgery, brain tumor, multiple sclerosis.
  • History of cancer, rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus, or polymyositis
  • Unintended weight loss of 20 pounds or more in the last year
  • Cauda equina syndrome
  • Ferromagnetic implants or other for MRI
  • Uncompensated congestive heart failure, unstable angina, poorly controlled arrhythmia, active systemic infection end stage renal disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Other
    LIFU/Sham

    double-blind, sham-controlled, crossover study in N=66 individuals with Chronic Back Pain

    Device: low intensity focused ultrasound (LIFU)

  • Other
    Sham/LIFU

    double-blind, sham-controlled, crossover study in N=66 individuals with Chronic Back Pain

    Device: low intensity focused ultrasound (LIFU)

Interventions

  • Devicelow intensity focused ultrasound (LIFU)

    Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.

06

What researchers measure

Primary outcomes

  1. Measures of Central Sensitization - Thermal Pain Threshold

    For the first measure, the probe is placed on the skin on the ventral aspect of the forearm on the nondominant arm. The temperature is set at 32°C and the temperature is increased at a rate of 1°C/s to a maximum of 52°C. Participants will be asked to press a button when the heat reaches a painful level. The outcome is the temperature at this level. Heat PT are averaged over three trials each separated by 40 seconds. Thermal PT will be performed prior to and after LIFU. On each trial, the thermode is moved to a different site on the forearm to avoid sensitization and response suppression of cutaneous heat receptors.

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays

  2. Measures of Central Sensitization - Temporal Summation of Pain

    The second measure refers to the perception of increasing pain in response to repeated same noxious stimuli delivered at a frequency of \> 0.33 Hz. Temporal summation of pain serves as a proxy measure of pain facilitation and CS. Individuals with enhanced temporal summation of pain have facilitated ascending nociceptive processing and reduced pain-modulatory capacities. Following the temporal summation of pain paradigm, three stimulus trains of trapezoid heat pulses of 1.5 s duration will be delivered to the dorsum of the dominant hand at an inter-pulse interval of 2.5 seconds at individual subject heat pain of 6/10 on numeric pain rating scale. A total of 5 stimuli will be delivered per train. Participants will be required to rate each stimulus (0-10). The Δ scores from 5th to 1st stimulus of each train will be averaged.

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays

  3. Measures of Central Sensitization - Conditioned Modulation of Pain

    A type of counter-irritation paradigm that can be used as a proxy measure for descending anti-nociceptive or pain modulation activity. CPM involves presentation of a conditioning pain stimulus to a remote area of the body while a nociceptive (test) stimulus (TS) is applied to the contralateral (heterotopic) area. We will employ conditioned modulation of pain according to using a sequential conditioning-test stimulus protocol as recommended by. The test stimulus consists of a two-minute thermal stimulus applied with the thermode at a rating of 5/10 on the numeric pain rating scale. Participants will rate their perceived pain (0-10, numeric pain rating scale) every 15 seconds. This will be performed pre/post the conditioning stimulus. The conditioning stimulus will be a cold pressor test.. The non-dominant arm will be immersed in a cold-water bath (12°C) for two minutes. This method recruits inhibitory conditioned modulation of pain because it is a strong nociceptive stimulation.

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays

Secondary outcomes

  1. Neurologic Pain Signature

    A secondary outcome is the pain intensity and magnitude of the NPS in response to evoked thermal pain using task-based functional magnetic resonance imaging.

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays

  2. Tonic Pain Signature

    A secondary outcome is the pain intensity and magnitude of Tonic Pain Signature in response to tonic pain using resting-state functional magnetic resonance imaging.

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post sham

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — behavioral and imaging data

Supporting information: Statistical analysis plan, Analytic code

Time frame: data will be available after analysis of primary and secondary outcomes are completed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Apr 2, 2025
StartActual
Jan 15, 2025
Primary completionEst.
Jan 26, 2028
CompletionEst.
Jan 26, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06906211
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Jan 15, 2025
Primary completion
Jan 26, 2028 (estimated)
Completion
Jan 26, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Mary R Lee, MD
Contact
mary.lee3@va.gov
202-745-8000 ext. 58128
Evan Evan Lindeman, MS
Contact
evan.lindeman@va.gov
Mary R Lee, MD
principal investigator · Washington D.C. Veterans Affairs Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion